MedTrace Logo

In Vivo Evaluation of Anti-inflammatory and Antithrombotic Health Promoting Properties of Extra Virgin Olive Oil Versus Classic Table Olive Oil in Healthy Subjects

NCT07784166 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-08-25

No results posted yet for this study

Summary

This study aims to evaluate the in vivo antithrombotic and anti-inflammatory effects of extra virgin olive oil daily consumption at recommended doses for 1 month compared to similar consumption of classic table olive oil, in the blood plasma and platelets of healthy donors

Conditions

  • Antiplatelet
  • Antithrombotic
  • Anti-Inflammatory Agents, Non-Steroidal

Interventions

OTHER

Olive Oil 1

1st arm: 18 healthy volunteers consumed 30 mL of extra virgin olive oil (EVOO) daily for 28 days. Blood samples and biochemical assays were conducted just before (day 0) and after (day 28) this dietary intervention

OTHER

Olive oil (placebo) 1

2nd arm, 18 other healthy volunteers consumed 30 mL of plain classic table olive oil (CTOO) daily for 28 days.

OTHER

Olive Oil 2

3rd arm, 9 healthy volunteers initially consumed 30 mL of EVOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of CTOO daily for 28 days, in a crossover single blinded randomized design with the 3rd arm. Blood sampling and Biochemical Assays were conducted just before (day 0) and just after (day 28) each of these interventions

OTHER

Olive oil (placebo) 2

4th arm, 9 healthy volunteers initially consumed 30 mL of CTOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of EVOO daily for 28 days, in a crossover single blinded randomized design with the 3rd arm. Blood sampling and Biochemical Assays were conducted just before (day 0) and just after (day 28) each of these interventions

Sponsors & Collaborators

  • Democritus University of Thrace

    lead OTHER

Principal Investigators

  • Alexandros Tsoupras · Democritus University of Thrace

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07784166 on ClinicalTrials.gov